The rise of Viagra and its influence on the pharmaceutical landscape presents a intricate question for investors. While the first sales data were remarkable, the intellectual property has ended, leading to a deluge of off-brand alternatives that are eroding revenue. In addition, the sector is facing difficulties related to demographic trends and sh